In ER-negative disease , there was evidence for greater benefit from anthracyclines in the National Epirubicin Adjuvant Trial in patients with CD@ + tumours -LSB- hazard ratio ( HR ) = @ ; @ % CI @-@ @ -RSB- versus CD@-negative tumours ( HR = @ ; @ % CI @-@ @ ) .